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Background: [18 F]fluorodopa (FDOPA) positron emission tomography (PET) allows assessment of levodopa
(LDOPA) metabolism and is widely used to study Parkinson's disease. We examined how [18 F]FDOPA PET-derived
kinetic parameters relate the dopamine (DA) and DA metabolite content of extracellular fluid measured by
microdialysis to aid in the interpretation of data from both techniques.
Methods: [18 F]FDOPA PET imaging and microdialysis measurements were performed in unilaterally
6-hydroxydopamine-lesioned rats (n = 8) and normal control rats (n = 3). Microdialysis testing included baseline
measurements and measurements following acute administration of LDOPA. PET imaging was also performed using
[11C]dihydrotetrabenazine (DTBZ), which is a ligand for the vesicular monoamine transporter marker and allowed
assessment of denervation severity.
Results: The different methods provided highly correlated data. Lesioned rats had reduced DA metabolite
concentrations ipsilateral to the lesion (p < 0.05 compared to controls), with the concentration being correlated
with FDOPA's effective distribution volume ratio (EDVR; r = 0.86, p < 0.01) and DTBZ's binding potential
(BPND; r = 0.89, p < 0.01). The DA metabolite concentration in the contralateral striatum of severely (>80%) lesioned
rats was lower (p < 0.05) than that of less severely lesioned rats (<80%) and was correlated with the ipsilateral PET
measures (r = 0.89, p < 0.01 for BPND) but not with the contralateral PET measures. EDVR and BPND in the
contralateral striatum were not different from controls and were not correlated with the denervation severity.
Conclusions: The demonstrated strong correlations between the PET and microdialysis measures can aid in the
interpretation of [18 F]FDOPA-derived kinetic parameters and help compare results from different studies. The
contralateral striatum was affected by the lesioning and so cannot always serve as an unaffected control.
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For three decades, [18 F]fluoro-3,4-dihydroxyphenyl-L-
alanine ([18 F]FDOPA) positron emission tomography
(PET) has served as an imaging biomarker for dopamine
(DA) synthesis, storage, and turnover in the human brain
[1-6]. More recently, [18 F]FDOPA PET has been used
in the study of mouse [7,8] and rat [9,10] models of
Parkinson's disease (PD). The increasing availability of* Correspondence: mwalker@physics.ubc.ca
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in any medium, provided the original work is ptransgenic rodent models of PD which may recapitulate the
cardinal features of the disease, including disease progres-
sion, has spurred new interest in imaging the dopaminergic
system of rodents. Non-invasive molecular imaging such as
PET enables longitudinal measurements in rodent models
to be made and facilitates a direct comparison with the
human disease. [18 F]FDOPA traces the metabolic pathway
of exogenous levodopa (LDOPA), providing information
that is quite distinct from that given by ligands which
bind to either dopamine receptors, transporters, or
other targets within the dopaminergic system. One such
ligand is (+)-dihydrotetrabenazine (DTBZ), which binds ton Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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DTBZ binding informs on the density of VMAT2, from
which DA terminal integrity (i.e., denervation severity)
may be inferred [11,12]. Insights into the function of the
dopaminergic system can also be made by microdialysis.
The insertion of dialysis probes directly into the rodent
brain provides a means of sampling extracellular fluid
(ECF) which can then be assayed for various compounds,
including its dopamine and dopamine metabolite content.
The direct sampling of ECF and the quantification of DA
and DA metabolite concentrations within such samples is
a commonly available and well-used technique for in vivo
research, but the method is invasive and not well suited to
longitudinal investigations [13-15].
The results from microdialysis are relatively simple to
interpret as compared to the outputs from the kinetic
modeling of dynamic [18 F]FDOPA PET data, in which a
compartmental model is typically used to describe several
key steps that govern the tracer's time-course in the brain.
These steps include, among others, (1) transport of the
tracer across the blood–brain barrier as mediated by the
large neutral amino acid transporter [16]; (2) decarb-
oxylation of FDOPA to DA, catalyzed by aromatic amino
acid decarboxylase (AADC); (3) incorporation and stor-
age of DA into vesicles [17], mediated by the vesicular
monoamine transporter (type 2) [18]; (4) vesicular release
of DA into the synapse and its subsequent metabolism
via catechol-O-methyltransferase (COMT) and monoamine
oxidase (MAO) [19] either within the synapse or after
reuptake by the dopamine transporter [20]; and (5) washout
of metabolites into the circulation. Due to the complex
pathway traced by [18 F]FDOPA, many simplifications are
made to allow robust parameter estimates to be obtained
from the kinetic model. These simplifications necessarily
lead to greater ambiguity in the biological interpretations
for the various parameters. Given these complexities, a
direct comparison between [18 F]FDOPA PET and in vivo
microdialysis in the same animals is of great value.
In the current investigation, we make a comparison
between results from [18 F]FDOPA PET, [11C]DTBZ PET,
and in vivo striatal microdialysis to directly measure
DA and DA metabolites in normal control rats and in
rats unilaterally 6-hydroxydopamine (6-OHDA)-lesioned at
the substantia nigra pars compacta (SNc) [21,22]. We aim
to allow microdialysis data, either from previous literature
or future studies, to be put into perspective alongside
results from [18 F]FDOPA and [11C]DTBZ PET.
Methods
Animals, 6-OHDA lesioning, and microdialysis surgery
Procedures involving animals were approved by the
University of British Columbia's ethics committee and
followed the guidelines of the Canadian Council on
Animal Care. We report data from three normal control(age-matched, not sham-operated) and eight unilaterally
6-OHDA-lesioned [21,22] rats (Sprague Dawley, males,
from Charles River, St. Constant, Quebec, Canada). These
rats underwent multiple PET imaging sessions, as reported
in Walker et al. [10], before undergoing two microdialysis
sessions. The animals had free access to standard diet
and tap water. They were housed at 21°C with a 12-h
light cycle (light from 7 a.m. to 7 p.m.). Dopaminergic
denervation was produced by injection of 10 μg of
6-OHDA hydrobromide (Sigma-Aldrich, St. Louis, MO,
USA) dissolved in 4 μL of 0.05% ascorbic acid solution.
The injection co-ordinates (SNc) were as follows: an-
teroposterior (AP) −4.7 mm (from the bregma),
mediolateral (ML) −1.5 mm (from the midline), and
dorsoventral (DV) −7.9 mm (from the skull surface)
[23]. To protect noradrenergic nerve terminals, desip-
ramine (Sigma-Aldrich) was given at least 30 min prior
to surgery (25 mg/kg intraperitoneally (i.p.)). This ensured
selectivity for dopaminergic neurons [24]. Rats were 2.4 ±
0.5 months (average and standard deviation) old at the
time of lesioning. Denervation severity was determined
by [11C]DTBZ PET imaging, which was performed at
least 1 month after lesioning (2.1 ± 0.8 months) at which
time 6-OHDA-induced denervation is considered rela-
tively stable. The [18 F]FDOPA PET imaging sessions
were also performed at least 1 month after lesioning
(average of 3.5 months, maximum of 8.5 months post
lesioning). Microdialysis was performed after completion
of all PET imaging at 12 ± 3.6 months post lesioning. Sur-
gery was performed for implantation of a microdialysis
guide cannula (CMA 7, Harvard Apparatus, Holliston,
MA, USA) into the left and right striata at co-ordinates
AP +1.0 from the bregma, ML ±2.6 from the bregma, and
DV −3.0 from the skull. A headcap was built up around
the cannula using dental cement (Jet Acrylic, Lang Dental,
Wheeling, IL, USA) and secured to the skull with five
self-tapping bone screws (shaft diameter 1.17 mm,
shaft length 4.7 mm, Fine Science Tools, North
Vancouver, Canada). All surgeries were performed under
isoflurane anesthesia. Ketoprofen (5 mg/kg sc.) was given
for pain relief, and a local analgesic (bupivacaine, 2.5
mg/kg) was applied at the incision site.
Microdialysis
Following headcap surgery, rats were allowed 36 h of re-
covery. Microdialysis was then performed under isoflurane
anesthesia twice in each rat within the next 4 days, with at
least 1 day of recovery between microdialysis sessions.
The use of anesthesia replicated the conditions during
PET scanning and simplified the microdialysis procedure.
Each session began with the insertion of a microdialysis
probe (CMA 7, Harvard Apparatus) into each guide
cannula. These probes have a shaft length of 7 mm with a
2-mm-long cuprophane membrane (cutoff of 6,000 Da) of
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prepared by flowing sterile artificial cerebrospinal fluid
(aCSF) through them (CMA, Harvard Apparatus). The
aCSF flow rate was 0.5 μL/min, but 0.9 μL/min in a few
rats where extra dialysate was required (for other testing
not reported here). Dialysate collection began 2 h after
insertion of the probe to allow some recovery from po-
tential tissue damage caused by probe insertion. In both
sessions, 1 h of baseline data was first collected. This
was followed by injection (i.p.) of 40 mg/kg entacapone
(which inhibits peripheral COMT) in one session and of
benserazide/LDOPA (15 and 50 mg/kg, respectively,
with the LDOPA given 30 min after the peripheral
AADC inhibitor) in the other session. Entacapone was
obtained from a local pharmacy in pill form and ground
to a fine powder. Benserazide (Sigma-Aldrich), LDOPA
(Sigma-Aldrich), and entacapone were mixed in distilled
water, 0.05% ascorbic acid, and saline, respectively, for
injected volumes of 1 mL/kg.
Dialysates were collected from each probe at intervals
of 24 min and immediately injected (9 μL) onto a high-
performance liquid chromatography system consisting of a
pump (Series IV, Rose Scientific, Edmonton, Canada), pulse
damper (Scientific Systems Inc., State College, PA, USA),
injector with 20-μL injection loop (Rheodyne, IDEX Health
& Science, Oak Harbor, WA, USA), reverse-phase col-
umn (TSKgel super-ODS, 2-μm silica particles, 110-Å
pores, 2-mm i.d. × 10-cm length, Tosoh Bioscience,
San Francisco, CA, USA), and electrochemical detector
(Decade II, Antec, Fremont, CA, USA). The flow rate
was 0.18 mL/min, with a pressure of approximately
1,600 psi. Each liter of mobile phase contained 100 mL
methanol, 900 mL water, 6 g sodium acetate, 40 mg
ethylenediaminetetraacetic acid (EDTA), 4 mg sodium
dodecyl sulfate (SDS), and glacial acetic acid (to pH 4.0).
The electrochemical cell (VT-03, Antec) had a 2-mm glassy
carbon working electrode with a salt bridge reference
electrode. A 25-μm spacer was used. The applied voltage
was +650 mV; the cell and column were maintained at
38°C. Data were collected and analyzed using EZChrom
Elite (Agilent, Santa Clara, CA, USA).
Typical probe recoveries as measured at room
temperature in vitro were 24%, 26%, and 24% for DA
and the DA metabolites 3,4-dihydroxyphenylacetic acid
(DOPAC) and homovanillic acid (HVA), respectively, at
0.5-μL/min flow rate. The recoveries were, on average, 14%
at 0.9 μL/min. The in vitro measured probe recoveries were
used as estimates of the in vivo probe recoveries, thus
correcting for differences in recovery between probes and
allowing the relative dialysate concentrations to be com-
pared across rats. The procedure does not provide a highly
accurate measurement of the absolute concentration in
the ECF since the in vivo recoveries are known to differ
from those measured in vitro. Recoveries were combinedwith the measured calibration factor for each compound to
produce the concentrations reported here. The data include
those from baseline (average of both sessions), the
percentage change from baseline following injection of
benserazide/LDOPA (one session), and the percentage
change from baseline following injection of entacapone
(one session). The post-drug concentrations were found
by averaging data from 100 to 180 min post benserazide
injection (70 to 150 min post LDOPA injection) and from
90 to 150 min post entacapone injection. Reported times
are corrected for the time required for the sample to travel
from the probe to the collection vial. In our microdialysis
experiments using LDOPA, we did not pre-dose with a
COMT inhibitor since the chromatographic analysis can
separate DA and DA metabolites from 3-O-methyldopa
and because a relatively high dose of LDOPA was used.
The testing allowed assessment of the basal concentrations,
the central effects (if any) of entacapone, and the increase
in DA metabolite concentrations following LDOPA.
PET scanning and image analysis
Extensive details of the PET imaging and analysis proce-
dures are reported in Walker et al. [10] and are summarized
here. The results reported here are from one [11C]DTBZ
scan and two [18 F]FDOPA PET scans. For the [18 F]FDOPA
scans, a COMT inhibitor (40 mg/kg entacapone) and
an AADC inhibitor (10 mg/kg benserazide) were given
i.p. prior to the administration of the radiotracer (at 90
and 30 min, respectively). The scans are a subset of those
reported previously in Walker et al. [10], namely the scans
from rats that were subsequently available for microdialysis
and which did not include administration of tolcapone
prior to [18 F]FDOPA PET. Scanning was conducted
under 2.5% isoflurane gas anesthesia using the MicroPET
Focus120 small animal scanner (Concorde/Siemens,
Knoxville, TN, USA) [25]. Emission data were collected for
3 h ([18 F]FDOPA) or 1 h ([11C]DTBZ) and split into 26 or
17 frames, respectively. Frames had increasing durations,
in the range 30 to 900 s ([18 F]FDOPA) and 30 to 480 s
([11C]DTBZ). Data were fully corrected for randoms,
attenuation, scatter, normalization, and dead time. Images
were reconstructed by filtered backprojection. The spatial
resolution within the resulting images is <1.5-mm full width
at half maximum [25]. Blood was sampled from the tail
during [18 F]FDOPA scanning and assayed for radiolabeled
metabolites [26], following which a small fraction of
scans were discarded due to high concentrations of the
radiolabeled metabolite 3-O-methyl-6-[18 F]fluoro-L-dopa
([18 F]OMFD; >25%) or low concentrations of the parent
compound (<40%) at 160 min post tracer injection (i.e., in
scans for which peripheral COMTand/or AADC inhibition
was insufficient). Despite this, all rats had at least one [18 F]
FDOPA scan that was retained (most had two, in which
case the average result is reported).
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(CTI Concorde Microsystems). For each scan, three regions
of interest (ROIs) were placed on summation radioactivity
images, defining the left and right striata and the cere-
bellum. The ROI volumes were 0.022 cm3 (striatal) and
0.043 cm3 (cerebellum). In contrast to the data reported in
[10], the ROI for the cerebellum used for PET data analysis
was placed with the guidance of a co-registered atlas [27];
this improved the consistency of the data. Kinetic modeling
and analysis was performed using Matlab (The Mathworks,
Natick, MA, USA) with in-house software.
[11C]DTBZ was analyzed using Logan graphical analysis
with a cerebellum reference region [28], which estimates
the distribution volume ratio (DVR). The time after which
data are fitted, t*, was set to 30 min, and the k 2 term was
omitted [29]. The binding potential of DTBZ (BPND) was
calculated as BPND = DVR – 1.
[18 F]FDOPA was similarly analyzed using the Logan
plot, with the modification that the time-activity curve
(TAC) from the reference region was subtracted from
the striatal TAC prior to running the analysis [6]. The
estimated slope equals the effective distribution volume
ratio (EDVR), which informs on the distribution volume
of the striatal 6-[18 F]fluorodopamine (FDA) compartment
as compared to the reference region.
Extended Patlak graphical analysis [5,30], which includes
a term describing the loss of radiolabeled metabolites from
the sequestered compartment, was also applied to the [18 F]
FDOPA data. The analysis provided estimates of kref, the
rate constant that models the decarboxylation of FDOPA to
FDA and the sequestration of FDA in vesicles.
The asymmetry for results from both PET and micro-
dialysis was calculated as 1 minus the ratio of the value
from the ipsilateral side to the contralateral side; normal
control rats were hence expected to have an asymmetry
of 0 for all measures, with severely lesioned rats likely to
have asymmetries closer to 1 (maximum asymmetry).
The asymmetry in the DTBZ PET measure provides
the assessment of denervation severity [11,12].Correlation analysis and statistical testing
Data from PET and microdialysis were subject to regression
analysis using Matlab (The MathWorks). In each case,
Pearson's product–moment correlation coefficient (r)
was calculated, along with the probability of obtaining
the measured correlation by chance if the true correl-
ation was 0. Group comparisons between rats were
also made, with group assignment for lesioned rats
based on the DTBZ PET denervation severity measure.
For these inter-group comparisons (three groups, n ≥ 3
in each group), statistical analysis followed Fisher's
method of analysis of variance (ANOVA) followed by
post hoc comparisons using the least significant differencetechnique when the omnibus test found a significant
difference [31].
Results
For microdialysis measures, the concentration of DOPAC
was highly correlated with the concentration of HVA
(r = 0.83, p < 0.01) across all rats, with a relationship
not significantly different from direct proportionality.
These two DA metabolites were thus combined for
subsequent analysis.
Figure 1 shows the impact of 6-OHDA lesioning on
DA metabolite concentrations as measured in the ECF
by microdialysis. Lesioning caused a decrease in the metab-
olite concentration ipsilateral to the lesion, with the level
for severely lesioned (>80%) rats being significantly lower
than those for both the control group and the <80% lesion
group. On the contralateral side, the severely lesioned rats
had the lowest metabolite concentration across groups,
with the difference being significant when compared to
the <80% lesion group. Although the DA metabolite
concentration measured contralateral to the lesion in
the <80% lesion group was higher than the concentration
measured in controls, the difference was not significant.
Example PET images from a rat with a lesion of severity
0.90 (DTBZ PET measure) are shown in Figure 2. For
each tracer, the displayed images are summation im-
ages from the entire scan, with the color scale set to
the standard uptake value (SUV; equal to the activity
concentration divided by the injected dose per unit
body weight (kBq/cm3 per MBq/kg)).
Basal DA metabolite levels measured by microdialysis,
both ipsilateral and contralateral to the 6-OHDA lesioning,
were strongly correlated with striatal PET measurements
ipsilateral to the lesion. Conversely, the PET measures
(BPND from DTBZ PET, EDVR from FDOPA) on the
contralateral side appeared not affected by the lesioning,
with values not different from those for normal control
rats and not correlated with denervation severity nor with
the measured DA metabolite levels either ipsilateral or
contralateral to the lesion. The correlations to ipsilateral
PET measurements for 6-OHDA-lesioned rats are shown
in Figure 3, along with the various correlation coefficients
and regression lines (all r ≥ 0.86, p ≤ 0.006). When the
FDOPA PET-measured kref was considered rather than
the EDVR, the correlation with basal DA metabolite
levels was only slightly reduced (r = 0.83, p = 0.010) as
compared to that for the EDVR (r = 0.86, p = 0.006) in the
ipsilateral striatum. There was a trend (not significant) for
the ipsilateral kref to be correlated with the contralateral
basal DA metabolite concentration (r = 0.65, p = 0.08).
These results demonstrate that for 6-OHDA-lesioned rats,
microdialysis-measured DA metabolite concentrations
in the striatum contralateral to the lesioning are corre-









































































Figure 1 Basal microdialysis measurements. Basal DA metabolite levels measured by microdialysis in the striatum, estimated using in vitro
probe recoveries. (A) Results for striatum ipsilateral to the 6-OHDA lesion. (B) Results for striatum contralateral to the 6-OHDA lesion. The asterisk
indicates significant difference from the unlesioned control group, and the number sign indicates significant difference from the <80% lesion
group (p < 0.05). For unlesioned control rats, data from the left and right striata were averaged. Error bars represent standard errors on the mean.
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the BPND from DTBZ or the EDVR from FDOPA PET
within the same contralateral striata.
The asymmetry in the data was also considered, in part,
to reduce noise in the data that could be caused by sys-
tematic errors affecting both striata in an individual scan.
As shown in Figure 4, there was a significant correlation
(r = 0.93, p < 0.001) between asymmetry in DA metabo-
lites and asymmetry in DTBZ BPND. The line of identity
was contained within the bounds of the 95% confidence
limit on the line of best fit, despite the aforementioned
observations that DA metabolites in the contralateralFigure 2 Example PET images. PET images of a rat with a severe (90%) le
shown in units of SUV. The images show a horizontal section through the
in both images.striatum are correlated with the DTBZ BPND in the ipsi-
lateral striatum (thus reducing slightly the asymmetry).
Similar results (r = 0.95, p < 0.001) were found when
comparing the asymmetry in DA metabolites to the asym-
metry in the EDVR from FDOPA. On the other hand, there
was no asymmetry observed in DA concentrations as seen
in Figure 4C. The mean asymmetry for the DA concentra-
tion in lesioned rats was only 8%, not significantly different
from 0, with no trend for increased asymmetry with in-
creasing denervation severity. There was a trend for the
total DA concentration in ECF (average from both striata)
to be reduced with decreasing ipsilateral DTBZ BPND,sion. (A) [11C]DTBZ image. (B) [18 F]FDOPA image. Both images are
striatum; the intact (left) striatum is the region with the highest uptake
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BPND from DTBZ PET in ipsilateral striatum
y = 3420 x + 7800 
r = 0.89 
p = 0.003









EDVR from FDOPA PET in ipsilateral striatum
y = 16500 x - 1200
r = 0.86 
p = 0.006









EDVR from FDOPA PET in ipsilateral striatum
y = 13300 x + 7400 











































































































Figure 3 Correlation between basal microdialysis and PET. (A) Correlation between basal, ipsilateral DA metabolite concentrations and the
DTBZ PET-measured BPND in the ipsilateral striatum. (B) Correlation between basal, contralateral DA metabolite concentrations and the DTBZ
PET-measured BPND in the ipsilateral striatum. (C) Correlation between basal, ipsilateral DA metabolite concentrations and the FDOPA PET-measured
EDVR in the ipsilateral striatum. (D) Correlation between basal, contralateral DA metabolite concentrations and the FDOPA PET-measured EDVR in the
ipsilateral striatum. In all four graphs, the solid line represents the regression to the data from 6-OHDA-lesioned rats.









































































Figure 4 Asymmetry in microdialysis compared to PET. (A) Asymmetry in basal DA metabolite levels (DOPAC +HVA) compared to asymmetry in
DTBZ BPND. (B) Asymmetry in basal DA metabolite levels (DOPAC + HVA) compared to asymmetry in FDOPA EDVR. (C) Asymmetry in basal DA vs.
asymmetry in DTBZ BPND. Dashed lines in (A) and (B) show the line of identity, while in (C) the dashed line shows asymmetry equal to 0.
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p = 0.09). The average (median) DA concentration in
ECF for normal control rats was estimated at 60 nM,
and that for lesioned rats was 43 nM. The asymmetry
in DTBZ BPND provided our measure of denervation
severity; it ranged from 0.26 to 0.90 in these rats.
The contralateral DTBZ BPND was not correlated with
the ipsilateral DTBZ BPND (r = 0.1), which further con-
firmed that the unilateral injection of 6-OHDA did not
lead to a bilateral lesion; more specifically, it did not cause
a bilateral reduction in dopaminergic terminal density. A
trend was observed however in FDOPA kref when compar-
ing the two sides of the brain (r = 0.47, p = 0.12), although
there was no such correlation for the EDVR (r = 0.1).
Increases in dopamine metabolite concentrations
(DOPAC + HVA) following i.p. injection of benserazide/
LDOPA were observed by microdialysis. These increases
are regressed against the DTBZ PET-measured denerv-
ation severity in Figure 5. For the striatum contralateral
to the lesion, the increase in DA metabolite concentra-
tions did not depend on the severity of the lesion and
averaged 144%. For the ipsilateral striatum, a significant,
positive correlation was found between the denervation se-
verity (measured as the asymmetry in DTBZ binding) and
the percentage increase in DA metabolite levels (r = 0.7,
p = 0.015). For lesioned rats, the percentage increase in
DA metabolites in the ipsilateral striatum was not cor-
related with the increase in the contralateral striatum
(n = 8, r = 0.32, p = 0.4); this is unlike the normal control
rats where increases tended to be similar between the left
and right striata (as would be expected).
The percentage increases in the microdialysis-measured
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Figure 5 Microdialysis following acute LDOPA. Increases in DA metabo
following i.p. injection of 15 mg/kg benserazide (at t = 0 min) and 50 mg/
as the PET-measured asymmetry in DTBZ binding). (A) Results for the left s
(ipsilateral to the lesion). The solid lines in (A) and (B) show linear regressioare also shown in Figure 6 where they are compared against
the estimates of DTBZ BPND (Figure 6A), FDOPA EDVR
(Figure 6B), and FDOPA kref (Figure 6C) as estimated for
the ipsilateral striatum by PET. Significant correlations were
found between the percentage increase in DA metabolites
and the DTBZ BPND (r = −0.68, p = 0.02) and FDOPA
EDVR (r = −0.66, p = 0.03), with a non-significant trend
observed in the regression against FDOPA kref (r = −0.46,
p = 0.15). Figure 6D shows the absolute increase in DA
metabolites (rather than the percentage change) following
LDOPA as compared with FDOPA kref. A strong correlation
was found between these measures (r = 0.88, p < 0.001).
This correlation was slightly stronger than the correlations
between the absolute increase in DA metabolite concen-
trations and the FDOPA PET-measured EDVR (r = 0.77,
p = 0.006) and the DTBZ BPND (r = 0.81, p = 0.003).
Our tests with injection of 40 mg/kg entacapone alone
found no significant changes in DA and DA metabolite
concentrations in ECF as compared to those at baseline.
The average change in DA metabolites was −4% from
baseline, consistent with no effect of the drug. There
were no significant correlations between the change in
DA metabolite levels and the denervation severity.
Discussion
The results presented in Figure 3 indicate that in the
striatum ipsilateral to the lesioning, the EDVR of [18 F]
FDOPA PET is reduced. This reduction was strongly
correlated with the decrease in DA metabolite levels in
the ECF as measured by microdialysis in 6-OHDA-lesioned
rats. The observation of a reduction in DA metabolite
concentrations in the ipsilateral striatum, which is well
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ns to the data.
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EDVR from FDOPA PET in Right (ipsi.) Striatum











Figure 6 Microdialysis-measured effects of acute LDOPA compared to functional measures from PET. Correlations between the increases
in DA metabolite concentrations in striatal dialysates and PET measures of dopaminergic function. Data are for the striatum ipsilateral to lesioning,
following i.p. injection of 15 mg/kg benserazide (t = 0) and 50 mg/kg LDOPA (t = 30 min). (A) Comparison with DTBZ BPND. (B) Comparison with
FDOPA EDVR. (C) Comparison with FDOPA kref. (D) Comparison of the absolute increase in DA metabolites with FDOPA kref. In each panel, a solid
line shows the result of a linear regression to the data.
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good agreement with the literature [32]. The data reported
here are the first (to our knowledge) that directly compare
such changes in the ECF with the results from recently de-
veloped [18 F]FDOPA PET imaging in rats; the comparison
provides further verification of the imaging method since
the findings for the ipsilateral striatum are in agreement
with our predictions, considering the known effects of the
lesioning. The method could provide further insight into
the complexities of the dopaminergic system, somewhat
paralleling the work of Hume et al. [33] who used [11C]
raclopride (a dopamine D2/D3 receptor antagonist) PET
imaging together with microdialysis in a similar rat model
to study DA receptor supersensitivity after lesioning and
the effects of acute L-DOPA administration. The work of
Tsukada et al. [34] also makes use of similar techniques,using microdialysis to sample and analyze the various
metabolites that occur in the rat brain after injection of the
PET radiotracer L-[11C]-DOPA. The ability to distinguish
between different radioactively labeled compounds in the
ECF of the brain can be utilized to measure the metabolic
and kinetic profiles of new radiotracers for PET imaging
and to examine the effects of drugs on such profiles. In this
study, we found entacapone to have little or no impact on
DA and DA metabolite measures, supporting the view that
kinetic parameters obtained from [18 F]FDOPA PET images
are not altered by the use of this drug (which is required to
prevent rapid peripheral metabolism of the radiotracer by
COMT). Microdialysis is hence shown to complement PET
in several studies that investigate the dopaminergic system.
The data also indicate that functional changes occur in
the striatum contralateral to the 6-OHDA lesion, which
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nor in the steady-state vesicular storage of DA. In the stri-
atum contralateral to the lesion, there were no reductions
in [11C]DTBZ binding or in the EDVR of [18 F]FDOPA, but
there was a significant difference (42%) in DA metabolite
levels between the severely lesioned (>80%) rats and the
mildly lesioned (<80%) rats. The origin of this difference is
unclear since neither group's DA metabolite level was
significantly different from that of the control rats.
This lack of significance may be due to the low number
of control rats and the variability in the measurements.
It is possible that compensatory mechanisms lead to a
small increase in DA metabolite levels in the contralateral
striatum in mildly lesioned rats, and it appears likely that
other mechanisms lead to reductions in DA metabolite
levels in severely lesioned rats.
The suggestion of a reduction in DA metabolites in the
ECF in the contralateral striatum seen here is similar to the
trend observed in a previous work [35], but its exact cause
remains unknown. The location of our 6-OHDA lesioning,
the rostral end of the SNc, is caudal to the decussation of
the nigrostriatal projection [36] and was hence expected to
cause some damage to the crossed projection which origi-
nates in the ipsilateral SNc. Since crossed projections only
contribute a few percent of the total striatal innervations,
measures of VMAT2 density and DA storage in the contra-
lateral striatum are not expected to be sensitive to the de-
struction or impairment of crossed projections, consistent
with our observations of normal or near-normal VMAT2
density and DA storage in the contralateral striatum several
months after lesioning. A reduction in DA metabolites in
the ECF contralateral to the lesioning could be explained
if the loss of crossed projections results in a dispropor-
tionately large reduction in neuronal activity or if the
lesioning caused changes in other neuronal populations
(e.g., substantia nigra reticular (SNr), pedunculopontine
nucleus (PPN), or subthalamic nucleus (STN)) ipsilateral
to the lesion which result in bilateral functional changes
[37,38]. For extensive reviews of the 6-OHDA model,
see [22,39]. Note that although DA concentrations were
measured by microdialysis, our analysis purposefully
focused mainly on the DA metabolite levels since these
measures have proven to be much more consistent
across the literature and they are expected to be more
robust due to their far higher concentrations. That we
did not observe a significant decrease in DA content in
the ECF, nor any asymmetry between ipsilateral and
contralateral striata, is in agreement with results from
previous studies using 6-OHDA-lesioned rats with le-
sions of <95% and likely a result of compensatory mech-
anisms. In this respect, the DA concentration in ECF
differs greatly from the total DA in tissue [32], which is
a common measure of denervation severity and known
to be very well correlated with both DTBZ binding(used here for measuring denervation severity) and the
number of surviving DA terminals [11,12,29].
The increase in DA metabolites observed following
benserazide/LDOPA in the striatum contralateral to
lesioning was not dependent upon the degree of lesioning.
This implies that compensatory changes that may occur
in the contralateral striatum do not include a relative
upregulation in the LDOPA response, despite the afore-
mentioned decrease in the basal DA metabolite concen-
tration for the striatum contralateral to lesioning. On the
other hand, in the ipsilateral striatum, the more severely
lesioned rats had an exaggerated response to LDOPA
when considering the fractional increase in DA metabolite
levels above the basal levels. This suggests that DA release
is more dependent on the availability of exogenous
levodopa in the ipsilateral (lesioned) striatum as compared
to the contralateral striatum and to normal controls. The
functional consequences of 6-OHDA lesioning thus appear
to be different when considering the ipsilateral and contra-
lateral striata, which strongly indicates that the changes in
the contralateral striata are caused by different mechanisms
to those changes in the striatum ipsilateral to the lesion,
as may be expected [22]. Our data are consistent with
compensatory effects that change basal DA metabolite
levels in the contralateral striatum without a relative
upregulation in the LDOPA response in the contralateral
striatum and without an observable impact on the binding
of DTBZ or on the EDVR and kref of [
18 F]FDOPA for this
contralateral region. In the ipsilateral striatum, all of these
measures were reduced (although reductions in kref were
attenuated [10]).
The absolute LDOPA-induced increase in DA metab-
olites in ECF was expected to be strongly correlated to
the FDOPA PET-measured kref. Recall that kref represents
the rate-limiting steps for the conversion of exogenous
LDOPA into vesicular-stored DA. A reduction in kref im-
plies a reduction in the proportion of exogenous LDOPA
converted into DA within the corresponding brain region,
as compared to the proportion that is metabolized in the
periphery. It is hence reassuring that measures of kref and
the absolute LDOPA-induced increase in DA metabolites
were strongly correlated. Basal DA metabolite levels
appeared to be most strongly correlated with the degree
of terminal loss in the ipsilateral striatum which is well
quantified by the DTBZ BPND, which is linearly related
to the total DA storage capacity as estimated via the
FDOPA EDVR in 6-OHDA-lesioned rats [10].
The reported DA and DA metabolite concentrations are
those found after correction for probe recovery, using the
in vitro measured recovery as an estimate of the in vivo
recovery. It is known that these recoveries differ, and the
values reported are hence not highly accurate measure-
ments of levels in the ECF but are expected to be propor-
tional to those values. The use of two different perfusion
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coveries, and to ensure that this procedure did not confound
the results, we added probe perfusion rate as a covariate to
a linear model (analysis of covariance (ANCOVA)); the rate
was found to have no significant effects on the estimated
DA metabolite levels.
The presented data provide a crucial link between
two important investigative techniques: microdialysis
(with analysis of DA and DA metabolites) and PET imaging
(using [18 F]FDOPA and [11C]DTBZ). The investigation
provides a means of relating data from these two tech-
niques, but careful attention should be paid to the poten-
tial model-specific nature of the observed correlations:
the reported findings are from the unilateral 6-OHDA
rat model, with measurements made several months after
an acute lesion. The effects of lesioning are expected to
stabilize within 1 month and to far exceed age-related
changes that could take place between the time of PET
imaging and microdialysis. This view is strongly sup-
ported by the data, for example, the correlation found
when assessing asymmetry (Figure 4), and also by our
previous analyses of the effects of aging in this model
[40]. We expect the observed relationships between the
results from the various techniques to be applicable to
some other models, but different relationships might be
expected in models that differ greatly from that used
here. Our comparison enables informed predictions of, for
example, microdialysis-measured DA metabolite concen-
trations, using as an input the data collected at various
time points throughout a longitudinal PET study. Different
investigations may hence be compared in this way to as-
sess their agreement. In addition to this, the comparison
aids in the interpretation of results from [18 F]FDOPA
PET imaging, providing reassurances that the biological
interpretations assigned to the various parameter estimates
(i.e., EDVR and kref ) are valid. The presented data build
on our previous work [10], which examined the effects of
central COMT inhibition on [18 F]FDOPA PET parameter
estimates, and made a comparison between [18 F]FDOPA
and [11C]DTBZ PET measures in these lesioned rats. Also
crucial to the verification of [18 F]FDOPA PET method-
ology for rodent imaging was the work of Kyono et al.
[9] who compared the results from [18 F]FDOPA PET in
unilaterally 6-OHDA-lesioned rats (lesioned at the striatum
rather than at the SNc as here) with assays of brain homog-
enates (measurement of DA and DA metabolites in striatal
tissue) and brain sections (tyrosine hydroxylase immuno-
histochemistry) and with results from behavioral testing.
Results from imaging closely matched those from immuno-
histochemistry, with tracer uptake also correlating strongly
with DA (and DA metabolite) concentrations in tissue
and with turning behavior. These previous works dem-
onstrated the utility of [18 F]FDOPA PET imaging in rats
and verified that such imaging was sensitive to the effectsof 6-OHDA lesioning and pharmacological reduction
in DA turnover. Using in vivo microdialysis, we furthered
these works by measuring the DA and DA metabolite con-
tent in the ECF (as opposed to the whole tissue) at baseline
and following the administration of LDOPA, providing
greater verification of the imaging method and providing
new insights into the changes that can take place in the stri-
atum contralateral to lesioning in the 6-OHDA model.
Conclusions
To conclude, microdialysis and PET ([18 F]FDOPA and
[11C]DTBZ) are sensitive techniques for assessment of the
functionality of the dopaminergic system and may both
be crucial in furthering our understanding of diseases
such as Parkinson's. These techniques are vastly different
(invasive direct sampling vs. non-invasive neuroimaging)
and provide distinct information regarding the dopa-
minergic system. In some cases, as found here in the
striatum ipsilateral to 6-OHDA lesioning in the rat, the
results may be highly correlated. In other cases, such as for
the striatum contralateral to the lesioning in this model,
these metrics of dopaminergic function may diverge. Such
observations can provide insights into specific functional
changes occurring at the molecular level, highlighting the
synergy of multimodel investigations.
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